Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, MultiCenter, Randomized, Double-blind, Placebo-controlled Study of TAS-102 in Patients with Chemotherapy-Refractory Advanced Colorectal Cancer

Trial Profile

A Phase II, MultiCenter, Randomized, Double-blind, Placebo-controlled Study of TAS-102 in Patients with Chemotherapy-Refractory Advanced Colorectal Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tipiracil/trifluridine (Primary)
  • Indications Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 01 Jan 2020 Results of pos hoc analysis for substudy of RECOURSE (n=210) and phase II J003 (n=112) assesing pharmacokinetic data of Tipiracil/trifluridine exposure and pharmacodynamic markers such as chemotherapy induced neutropenia (CIN) and clinical outcomes, published in the Annals of Oncology.
    • 21 Jan 2017 Results from this and other phase 3 trial presented at the 2017 Gastrointestinal Cancers Symposium
    • 11 Oct 2016 Results reporting integrated safety summary for FTP/TPI using data from this and seven other trials presented at the 41st European Society for Medical Oncology Congress
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top